{"id":"tp-36267","type":"article-newspaper","title":"Tezspire Trial Shows Higher EoE Remission Through 52 Weeks","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/36267","datePublished":"2026-10-21T03:00:38.000Z","dateModified":"2026-10-21T03:00:38.000Z","language":"en","abstract":"At 24 weeks, histologic remission reached 64.8% and 68.9% across two doses, versus 3.5% with placebo; swallowing symptom scores also fell.","section":"Business","references":[]}